Release Date: November 28, 2007
Expiration Date: November 28, 2008
This educational activity is specifically designed for medical oncologists, dermatologists, researchers, and other physicians, physicians-in-training, and healthcare professionals interested in and/or involved in the care of patients with melanoma and its consequences.
This online activity is the video representation of a symposium from the annual US Melanoma meeting in October of this year, titled “The Evolving Role of CTLA4 in Melanoma.” This very exciting antibody is the focus of the entire program and several internationally known experts involved in research and treatment present it’s mechanism of action, issues related to autoimmunity, and antitumor activity induced by these new agents. This Webcast is designed to be a reliable resource for clinicians who manage the therapy of people who are diagnosed with melanoma.
After completing this activity, the participant will be able to:
- Identify the mechanism of CTLA-4 function as it relates to T cell activation and immunotolerance
- Review issues concerning immune-related adverse events associated with the administrations of CTLA-4 antibodies, including autoimmunity
- Recognize the antitumor activity induced by agents mediating CTLA-4 blockade
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex®, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing generic names of several to ensure impartiality.
All faculty participating in an Imedex activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity.
Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.
1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
| Alexander M.M. Eggermont, MD, PhD |
Boehringer-Ingelheim Pharmaceuticals, Inc.2; FSK Bio2; Genta Incorporated2; MERCK & CO., INC.1; NovaRx Corporation2; Novo-Nordisk A/S2; Sanofi-Pasteur Inc2; Schering-Plough Corporation1,2; Synta Pharmaceuticals Corp;2 |
| John M. Kirkwood, MD |
Eleos Inc.2; Intrexon Corporation2; Pfizer Inc1; Schering-Plough Corporation3 |
| Antoni Ribas, MD |
Pfizer Inc1,2 |
| Jedd D. Wolchok, MD, PhD |
Pfizer Inc2 |
All materials are included with the permission of the authors.
| John M. Kirkwood, MD |
Bristol-Myers Squibb Company1 |
| Jeffrey S. Weber, MD, PhD |
Bristol-Myers Squibb Company1, Mederex Inc1 |
| Jedd D. Wolchok, MD, PhD |
Bristol-Myers Squibb Company2 |
Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:
Keith Steward, MD, MBA, owns shares of Pfizer Inc and Johnson & Johnson, as well as stock options for AmerisourceBergen.
Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.
Kenneth Richardson, MD, Bradley Bongiovanni, ND, and Becky Lynch, RN, own stock options for AmerisourceBergen.
This activity is sponsored by Imedex, LLC.
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.
For questions regarding the accreditation of this activity, please contact
Imedex
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751-7334
Email: elearning@imedex.com
This Webcast may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
The opinions expressed in this Webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex.
The following companies have provided unrestricted educational grants in support of this activity: Bristol-Myers Squibb Company and Medarex Inc.
| System Requirements: |
 is required for proper viewing. Click here to download
- Pentium 500 processor or greater
- Windows 98/NT/2000/XP or Mac OS 9/X
- Microsoft Internet Explorer 5.5 or later
(Firefox browser currently not supported)
- 128 MB of RAM
- Monitor settings: High color at 800 x 600 pixels
- Sound card and speakers
Audio troubleshooting
For general troubleshooting concerning audio or video playback issues consult the following Web link: http://support.microsoft.com/kb/306317.
|
|
